A Phase 3 prospective, randomized, multicenter, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-Matched, living donor kidney transplants

Awarded By

Contributors

Start/End

  • May 21, 2018 - April 30, 2028